Skip to content

National Breast and Thyroid Screening After a Treatment Received Against a Cancer During Childhood

National Breast and Thyroid Screening After a Treatment Received Against a Cancer During Childhood

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03183401
Acronym
DENACAPST
Enrollment
2000
Registered
2017-06-12
Start date
2017-07-09
Completion date
2019-10-31
Last updated
2017-06-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early Detection of Cancer

Keywords

childhood cancer survivor

Brief summary

The DENACAPST programme represents an important initiative to provide near nation-wide roll-out of an important cancer surveillance program for childhood cancer survivors. The program is based on internationally recognized standards in cancer surveillance, which were developed by the International Guideline Harmonization Group (IGHG) with support of all relevant stakeholders in cancer survivorship research and clinical work in Europe, Canada and the United States and recognized French recommendations about breast screening for women at high risk of cancer. With this programme, French centers organized themselves to provide to childhood cancer survivors adequate medical attention, which includes close medical surveillance for breast/thyroid cancer where appropriate, based on adequate risk stratification. The aim of the study is to analyze if the recommendations about breast and thyroid cancer screening are followed in this population and secondly to provide more informations about these second cancers and about the screening.

Detailed description

Every center which has patient at risk can participate. Main inclusion criteria : French childhood cancer survivor (5 years or more of delay with the treatment) - becoming adult - with a past history of radiotherapy at the age of 20 years or before, with a significant dose irradiation on the thyroid or the breast The inclusion of patients are validated by one team Thyroid screening programme is based on US each 2 years Breast screening programme is based mainly on MRI each year

Interventions

None listed

Sponsors

Institut National de la Santé Et de la Recherche Médicale, France
Lead SponsorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* childhood cancer survivor, and * treated with radiotherapy * health status compatible, and * have had a long-term follow-up consultation describing a personalized post-cancer plan and, * informed consent signed by patient \+ Inclusion criteria for breast screening * being a woman and being 25 years or more for breast cancer screening, with a minimum delay of 8 years after radiotherapy, or * with a significant irradiation dose to the breast (Irradiation that delivered at least 10 Gy on at least part of the breast (v 5\> 10 Gy) or on the mammary bud (v 100\> 10 Gy) - (centrally validated dose) or received TBI (Total Body Irradiation)\> 8 Gy according to a bi-fractioned scheme or\> 6 Gy in single dose) +Inclusion criteria for thyroid screening: * being a man or a woman and being 18 years or more for thyroid cancer screening with a minimum delay of 5 years after radiotherapy, and, * with a significant irradiation dose to the thyroid (Irradiation having delivered at least 3 Gy on the thyroid (v100\> 3 Gy), or having received a TBI (Total Body Irradiation)\> 2 Gy, and / or treatment with 131i-metaiodobenzylguanidine), and

Exclusion criteria

* life expectancy \<10 years due to other pathology * patient in regular follow-up within the framework of a genetic susceptibility (ex li fraumeni) * person placed under safeguard of justice \+

Design outcomes

Primary

MeasureTime frameDescription
follow of cancer screening recommendations2 yearsnumber of persons at risk found percentage of persons at risk contacted who answered percentage of persons contacted, who answered, who accepted the screening

Secondary

MeasureTime frameDescription
description of thyroid cancer screening2 yearsevaluation of the programme
description of breast cancer screening2 yearsevaluation of the programme
description of second cancers2 yearsanalyze of the histological data
psycho social analyze2 yearsevaluated by auto-questionaries :initial / final and comparison with persons who accepted to answer but who did not accept the screening

Countries

France

Contacts

Primary Contactcharlotte demoor-goldschmidt, Dr
denacapst@inserm.fr+331 42 11 41 40

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026